Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib, Endocrine Therapy, and Brain Radiotherapy in HR+/HER2- Advanced Breast Cancer with Brain Metastases
NCT07539753Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by Nanfang Hospital, Southern Medical University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07539753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539753.